We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


DIAGAST develops, manufactures and markets reagents and automated systems for blood group determination. Its wide pro... read more Featured Products: More products

Download Mobile App

Diagast Presents Latest Immunohaematology Solutions at MEDLAB Middle East

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)
Image: DIAGAST at MEDLAB Middle East (Photo courtesy of DIAGAST)

DIAGAST (Loos, France) participated in the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27 where it presented its latest immunohaematology solutions and also organized a scientific workshop for Blood Transfusion Day.

Blood transfusion is at the heart of healthcare professionals’ concerns. From the donor to the patient, there are many challenges to be met to ensure the compatibility of transfusions. DIAGAST is a worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. The company develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST offers high performance product ranges and automated systems, guaranteeing the quality of transfusion diagnosis and patient safety.

At MEDLAB Middle East 2022, DIAGAST showcased its QWALYS 3 EVO automated system which is the only fully-automated system on the market using the magnetization of erythrocytes, a process that no longer requires washing and centrifugation steps. DIAGAST’s Erythrocyte Magnetized (EM) technology is based on Red Blood Cells (RBC) magnetization. This innovative solution enables avoiding washing and centrifugation steps usually associated to traditional immunohaematology testing. It uses a patented high-density solution (NanoLys) which creates a barrier that blocks non-specific antibodies which could interfere when performing direct and indirect antiglobulin tests. A latest-generation and fully-automated system with high throughput, large loading capacity and STAT function among others, QWALYS 3 EVO is the benchmark instrument for all laboratories, blood banks, blood transfusion centers and hospitals.

Related Links:

Gold Supplier
Pipette Tips
Sapphire Pipette Tips
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus
Washer Dispenser
Chemiluminescence Analyzer
DZ-Lite 3000 Plus

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Guidance UTI provides personalized results in less than one day from receipt at lab (Photo courtesy of Pathnostics)

Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes.... Read more


view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more


view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.